期刊
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 19, 期 10, 页码 2307-2323出版社
WILEY
DOI: 10.1111/jcmm.12625
关键词
microRNA; ncRNA; biomarker; biological fluid; non-invasive
资金
- Ikerbasque Foundation for Science
- Starmer-Smith Memorial Fund
- Ministerio de Economia y Competitividad of Spanish Central Government
- Consejerias de Industria Comercio y Turismo and Sanidad of Basque Government
- Asociacion Espanola Contra el Cancer (AECC)
- Diputacion Foral de Gipuzkoa
- AECC
The gold standard for cancer diagnosis remains the histological examination of affected tissue, obtained either by surgical excision, or radiologically guided biopsy. Such procedures however are expensive, not without risk to the patient, and require consistent evaluation by expert pathologists. Consequently, the search for non-invasive tools for the diagnosis and management of cancer has led to great interest in the field of circulating nucleic acids in plasma and serum. An additional benefit of blood-based testing is the ability to carry out screening and repeat sampling on patients undergoing therapy, or monitoring disease progression allowing for the development of a personalized approach to cancer patient management. Despite having been discovered over 60years ago, the clear clinical potential of circulating nucleic acids, with the notable exception of prenatal diagnostic testing, has yet to translate into the clinic. The recent discovery of non-coding (nc) RNA (in particular micro(mi)RNAs) in the blood has provided fresh impetuous for the field. In this review, we discuss the potential of the circulating transcriptome (coding and ncRNA), as novel cancer biomarkers, the controversy surrounding their origin and biology, and most importantly the hurdles that remain to be overcome if they are really to become part of future clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据